Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures, and commercialises medicines for the treatment of oncology, autoimmune, cardiovascular, and metabolic, ophthalmology, and other major disease areas, announced on Thursday that it presented for the first time the preclinical data of IAR177 as a poster in ACR Convergence 2026 held in Orlando, Florida.

IAR177 is a bispecific antibody that targets IL-6 and TL1A simultaneously and is designed to overcome the therapeutic ceiling of various rheumatic diseases. Its unique epitope is designed to prevent immune complex formation and reduces immunogenicity risk, while it also blocks IL-6 in its different states.

In-vitro and in-vivo models of rheumatoid arthritis showed a better response than single-target blockade, indicating potential in suboptimal responders and refractory patients. Studies in mice validated this activity, and its pharmacokinetic profile in monkeys supports high-concentration formulation for infrequent subcutaneous dosing.

Founded in 2011, Innovent has launched 20 products. It has one asset under NDA review, six in Phase 3 or pivotal trials and 20 more molecules in early clinical stages. The company has also entered more than 30 strategic partnerships, with an aggregate value of over RMB350bn.